The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
ESL spoken about on Vox podcast today. Alan Green seemed to think ESL had upside to 50p with a recovery situation. Mentioned the ESL name purchase as a sign that this is a recovery for the company and DBAY.
Sorry - are we expecting news tomorrow? Thanks
Laughingravy - it's in the 14th May RNS. Within the R&D Section.
Copied and pasted:
R&D
In May 2019, Primerdesign launched its next generation genesig® q32 qPCR molecular testing instrument ("q32"). As stated at the time of AIM IPO, Novacyt has utilised some of the funds to focus on product development, and the q32 is a direct result of this investment. The q32 is a larger genesig® real-time qPCR instrument, which provides customers with a faster and higher throughput solution for Novacyt's genesig® real-time PCR kits. The q32 complements the smaller, portable genesig® q16 instrument ("q16"), which is used in laboratories and the field, and provides customers with an alternative instrument when faced with multiple terrain and off-site testing challenges.
The q32 provides test results within 60 minutes using genesig® kits, making it one of the fastest qPCR instruments on the market due to its rapid heating and cooling capabilities and unique lid design. Like the q16, the q32 is robust and, therefore, highly reliable. It allows the analysis of up to 32 patient samples in tube or strip format, using fluorescence detection technologies. The q32 software also allows users to experience a quick and easy operation for all genesig® kit applications with a straightforward setup process.
During the year, Primerdesign also completed the design and development of the molecular respiratory panel based on a 384 well plate format for use by its North American business partner in their CLIA approved diagnostic testing laboratory network. Primerdesign designed the multiplex test to identify 37 respiratory pathogens, which makes it one of the most comprehensive respiratory panels available in the market today. In addition to identifying a large number of respiratory disease pathogens, the new diagnostic product was designed with proprietary freeze-drying technology to stabilise the product to optimise its ease of use and performance.
Primerdesign will supply this product under a five-year manufacturing agreement as its partner launches the new respiratory panel in the US market through its own clinical testing laboratories to provide a Laboratory Developed Diagnostic Test ("LDT") result for its customers.
CEO and Non-exec director bought shares on the 15th May. That shows confidence!
Jotting down some of the positive things to come soon by RNS. Please feel free to add anything I have omitted:
- Overall sales updates
- US OEM/pharma deal
- Rest of the world deals and sales
- Update on UK sales and progress with AZ / GSK partnership
- Full details and announcement on the release of the Exsig q32 instrument (results in 60 mins)
- Details and release of the portable testing instrument Gensig q16 (strip format samples and software platform are one aspect of this)
- Full details of the 384 well plate respiratory panel
- And importantly, launching in June; Direct-to-PCR extraction reagent called Exsig™ Direct to remove the need for RNA extraction reagents containing magnetic-beads. This reagent may now launch in two formats to accommodate different laboratory work-flows. The products are undergoing final clinical validation and expected to launch during June 2020.
A fantastic series of RNS’ are due in in the short term on which I can see this making new highs.
Thanks for mentioning Van. If we go in that direction and to new highs that would be fantastic, even if Zac’s target isn’t met. We have achieved a firm position at around £4 now for some time with consolidation so one would think that on good news we will be back up to previous highs. I just hope the results are presented in a way that doesn’t throw the market off, as they will certainly not be representative of current business trading.
Zac Mir of Share Talk, £4 should be broken with a new target of £7.50!
So on the balance of probability are we thinking that TF are our US partner? I.e. the US partner that has been talked about by the company for quite some weeks but not announced?
Thanks
Yes, thank you Van. Appreciated and necessary to get the word out there.
Sorry, it was the interview the CEO gave around a month ago. The price dropped straight after. He mentioned order numbers and the market didn't like it / was expecting more.
Just something to consider really, although as somebody noted yesterday, that was then and this is now - NCYT has progressed hugely and cemented itself as a market leader, and I believe the market now sees the company in a much better/higher profile light.
Well done all who have held and rode this today. What an incredible experience with this share so far. I bought more at 370 at the end of the day as I think this will easily rise to 500-600p next week with a good RNS. There was so much momentum today, I expect that will carry into next week.
There does come a point at which one wonders if this will come crashing back down to earth. I suppose we will see more rises and corrections as we did today going forwards. We have, with this share, seen a drop in the share price on an RNS that gives sales figures lower than than the market was hoping for. Something to bear in mind.
Overall this has still got further to go.
Agreed. I have asked them who's antibody test they are using.
Looking very briefly at the the Randox labs test - our test appears far superior. Quicker and more accurate, but I am not qualified to judge fully.
Just had this from a private surgery:
Testing
PCR antigen testing, in the acute phase of the illness, is currently in the hands of the NHS. Randox laboratories may be able to supply these tests in the future, but are currently sold out.
Antibody testing is useful when you have recovered from a possible Covid-19 infection, to confirm that you have developed a degree of immunity. We have a limited supply of these tests, which we believe are of sufficient sensitivity and specificity to give accurate results.
Antibody testing should be done when 14 days have elapsed since your first symptoms, or you are fully recovered. This would involve coming to the practice to have some blood taken, with the result being available in 15 minutes. The only charge would be for the 15 minute consultation.
We expect that similar tests will shortly be available from Public Health England via Amazon and Boots, but availability may be limited.
7AM Monday RNS. It's almost a certainty unless there is something big brewing which needs further time to execute before the next RNS.
...RNS first thing Monday.
Afternoon chaps - what are we all thinking in terms of timing of news or an update? The trial is 8 weeks, one would expect an update after 2 or 4 weeks?
Thanks
Agreed - this will bounce around between now and the end of the trial or when positive news is released. Buy the dips. I am hoping for an entry around 50p.
A great buying opportunity at this stage. I expect 225p with the next news.
Are we expecting an update on Friday - I would think so. Order updates, or further distribution and production partners?
Bought in further at 182 :)
Already in profit. Very nice.